Taxotere as a cornerstone treatment of NSCLCGIACCONE, Giuseppe.Lung cancer. 2005, Vol 50, issn 0169-5002, 43 p., SUP2Conference Proceedings

The potential of antiangiogenictherapy in non-small cell lung cancerGIACCONE, Giuseppe.Clinical cancer research. 2007, Vol 13, Num 7, pp 1961-1970, issn 1078-0432, 10 p.Article

The role of new agents in the treatment of non-small cell lung cancerBROKER, Linda E; GIACCONE, Giuseppe.European journal of cancer (1990). 2002, Vol 38, Num 18, pp 2347-2361, issn 0959-8049, 15 p.Article

Preclinical perspectives on platinum resistanceKELLAND, L. R.Drugs (Basel). 2000, Vol 59, pp 1-8, issn 0012-6667, SUP4Article

Tyrosine Kinase Inhibitors in Lung CancerTHOMAS, Anish; RAJAN, Arun; GIACCONE, Giuseppe et al.Hematology/oncology clinics of North America. 2012, Vol 26, Num 3, issn 0889-8588, viii, 589-605 [18 p.]Article

Novel approaches to the treatment of non-small cell lung cancerFERREIRA, Carlos G; HUISMAN, Cynthia; GIACCONE, Giuseppe et al.Critical reviews in oncology/hematology. 2002, Vol 41, Num 1, pp 57-77, issn 1040-8428Article

Optimizing chemotherapy and targeted agent combinations in NSCLCLYNCH, Thomas JR; KIM, Edward.Lung cancer. 2005, Vol 50, pp S25-S32, issn 0169-5002, SUP2Conference Paper

Drug Development: Portals of Discovery : Drug Development: What Experience Has Taught UsBATES, Susan E; AMIRI-KORDESTANI, Laleh; GIACCONE, Giuseppe et al.Clinical cancer research (Print). 2012, Vol 18, Num 1, pp 23-32, issn 1078-0432, 10 p.Article

Angiogenesis inhibitors. Drug selectivity and target specificity : Target specificity of effective anticancer therapeuticsRESISIS, Georgios; BROXTERMAN, Henk; GIACCONE, Giuseppe et al.Current pharmaceutical design. 2007, Vol 13, Num 27, pp 2795-2809, issn 1381-6128, 15 p.Article

Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignanciesLUDWIG, Heinz; KHAYAT, David; GIACCONE, Giuseppe et al.Cancer. 2005, Vol 104, Num 9, pp 1794-1807, issn 0008-543X, 14 p.Article

Early results of a randomized phase III trial of platinum-containing doublets versus a nonplatinum doublet in the treatment of advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer 08975GIACCONE, Giuseppe.Seminars in oncology. 2002, Vol 29, Num 3, pp 47-49, issn 0093-7754, SUP9Article

Dacomitinib, a new therapy for the treatment of non-small cell lung cancerBRZEZNIAK, Christina; CARTER, Corey A; GIACCONE, Giuseppe et al.Expert opinion on pharmacotherapy. 2013, Vol 14, Num 2, pp 247-253, issn 1465-6566, 7 p.Article

Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small-Cell Lung Cancer Working Group : Standardization for Use in the Clinical Trial SettingEBERHARD, David A; GIACCONE, Giuseppe; JOHNSON, Bruce E et al.Journal of clinical oncology. 2008, Vol 26, Num 6, pp 983-994, issn 0732-183X, 12 p.Article

Treatment of thymoma and thymic carcinomaGIACCONE, Giuseppe.Annals of oncology. 2000, Vol 11, pp 245-246, issn 0923-7534, SUP3Conference Paper

4th International Symposium on Targeted Anticancer Therapies (TAT 2006), 16-18 March, 2006, Amsterdam, The NetherlandsGIACCONE, Giuseppe; LOBBEZOO, Marinus W.Annals of oncology. 2006, Vol 17, issn 0923-7534, 65 p., SUP3Conference Proceedings

The role of gefitinib in lung cancer treatmentGIACCONE, Giuseppe.Clinical cancer research. 2004, Vol 10, Num 12, pp 4233s-4237s, issn 1078-0432, 2Conference Paper

Cell death independent of caspases: A reviewBRÖKER, Linda E; KRUYT, Frank A. E; GIACCONE, Giuseppe et al.Clinical cancer research. 2005, Vol 11, Num 9, pp 3155-3162, issn 1078-0432, 8 p.Article

Apoptosis: Target of cancer therapyFERREIRA, Carlos G; EPPING, Mirjam; KRUYT, Frank A. E et al.Clinical cancer research. 2002, Vol 8, Num 7, pp 2024-2034, issn 1078-0432Article

Exercise-induced spontaneous hemothorax insinuates trauma; yet unmasks a lament disorderHADITHI, Muhammed; VAN BOXEM, Ton J. M; GIACCONE, Giuseppe et al.Netherlands journal of medicine. 2001, Vol 59, Num 6, pp 292-294, issn 0300-2977Article

Clinical pharmacokinetics and administration of established platinum drugsO'DWYER, P. J; STEVENSON, J. P; JOHNSON, S. W et al.Drugs (Basel). 2000, Vol 59, pp 19-27, issn 0012-6667, SUP4Article

Role and Relevance of TrkB Mutations and Expression in Non―Small Cell Lung CancerHARADA, Taishi; YATABE, Yasushi; TAKESHITA, Masafumi et al.Clinical cancer research (Print). 2011, Vol 17, Num 9, pp 2638-2645, issn 1078-0432, 8 p.Article

Gefitinib. CommentariesCULY, Christine R; FAULDS, Diana; GIACCONE, Giuseppe et al.Drugs (Basel). 2002, Vol 62, Num 15, pp 2237-2250, issn 0012-6667, 14 p.Article

Genomics-based early-phase clinical trials in oncology: Recommendations from the task force on Methodology for the Development of Innovative Cancer TherapiesLIU, Stephen V; MILLER, Vincent A; LOBBEZOO, Marinus W et al.European journal of cancer (1990). 2014, Vol 50, Num 16, pp 2747-2751, issn 0959-8049, 5 p.Article

The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpressionROZ, Luca; ANDRIANI, Francesca; FERREIRA, Carlos G et al.Oncogene (Basingstoke). 2004, Vol 23, Num 56, pp 9102-9110, issn 0950-9232, 9 p.Article

Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: Limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or akt kinase pathwaysJANMAAT, Maarten L; KRUYT, Frank A. E; RODRIGUEZ, José A et al.Clinical cancer research. 2003, Vol 9, Num 6, pp 2316-2326, issn 1078-0432, 11 p.Article